High stable cell lines for manufacturing

High titer (HIT) clones generated from Amply™ Technology for cell optimization continue to display the same level of productivity up to more than 70 passages. This ensures the stability of your clone throughout the various phases of clonal amplification (RCB, DCB, MCB and WCB) and enables scale-up while passing them through bioreactors for therapeutic bioproduction.


All hybridoma projects treated from 2010 have enabled the generation of high producer clones that are currently being used in commercialised kits in the US, Europe and Asia.